EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 424 filers reported holding EXELIXIS INC in Q4 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,146 | -5.3% | 51 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $1,210 | -1.1% | 51 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $1,223 | +9.8% | 51 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $1,114 | +14.3% | 51 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $975 | -1.5% | 51 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $990 | +21.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $818 | -18.2% | 51 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,000 | 0.0% | 51 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | – | 51 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 51 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |